US Patent 5,994,409: Claim Scope, Expiration, Amifostine Coverage and Patent Landscape

US Patent No. 5,994,409 covers post-exposure treatment of chemotherapy- and radiation-induced toxicities with aminothiol compounds, including amifostine and its active metabolite WR-1065. The patent is method-of-treatment protection, not a composition-of-matter patent for amifostine. Its practical value depended on proving that the accused treatment occurred after toxicity appeared, rather than as prophylaxis before chemotherapy or radiation.

The patent issued on November 30, 1999. Based on the ordinary 20-year patent term measured from the earliest effective nonprovisional filing date, the US claims would have expired approximately in 2016-2017, subject to any patent-term adjustment. The patent therefore does not present a current US blocking right unless an unusual term adjustment or restoration applied. Patent No. 5,994,409 is not a current source of market exclusivity for amifostine.

What does US Patent 5,994,409 cover?

The patent has four principal coverage groups:

Coverage group	Claims	Subject matter
Post-chemotherapy toxicity treatment	1-13, 26, 36-39	Aminothiols administered after chemotherapy toxicity occurs
Post-radiation toxicity treatment	14-26, 37-39	Aminothiols administered after antineoplastic radiation toxicity occurs
Formula-specific amifostine treatment	27-30	Post-toxicity treatment using aminothiol phosphorothioates, including amifostine
Specific rescue indications	31-35, 40	Cisplatin nephrotoxicity, cisplatin neurotoxicity and treatment-induced xerostomia

The independent claims are method claims. They require:

A human subject.
Prior exposure to chemotherapy or antineoplastic radiation.
One or more toxicities associated with that exposure.
Administration of an aminothiol after the toxicity has occurred.
A therapeutically effective amount of a covered aminothiol, salt or hydrate.

The central inventive distinction is timing. The claims target therapeutic rescue after toxicity, not merely protection administered before or during cytotoxic treatment.

What aminothiol compounds are protected?

Claim 1 uses both named compounds and a broad chemical genus. The expressly identified compounds include WR-638, WR-2529 and WR-77913. Dependent claim 2 adds WR-1065, WR-151326, WR-151327, WR-3689, WR-2822, WR-255591, WR-2823 and WR-255709.

The claims separately identify:

Amifostine, also known as WR-2721.
WR-1065, the dephosphorylated active metabolite of amifostine.
WR-33278.
Active metabolites of WR-2721.
Prodrugs of active metabolites of WR-2721.
Pharmaceutically acceptable salts and hydrates.

The principal Markush structure in claims 1 and 14 is:

R1NH(CH2)nNH(CH2)mSR2

where:

R1 is hydrogen, C5-C7 aryl, C2-C7 acyl or C1-C7 alkyl;
R2 is hydrogen, phosphoric acid or a substituted aminothiol residue;
n and m independently range from 1 to 10.

Claims 27 and 29 use a narrower phosphorothioate structure:

R-NH-(CnH2n)-NH-(CmH2m)-S-PO3H2

where R is hydrogen or C1-C7 alkyl and m and n independently range from 1 to 10.

Amifostine falls within this narrower structure. The patent therefore has direct claim coverage for amifostine as a post-toxicity treatment, but the patent did not create exclusive ownership of the amifostine molecule itself.

Which toxicities fall within the patent claims?

Claim 7 lists:

Neurotoxicity
Nephrotoxicity
Ototoxicity
Cardiotoxicity
Alopecia
Mucositis
Xerostomia
Infertility
Pulmonary toxicity
Renal failure

The claims also contain narrower disease-specific coverage.

Cisplatin nephrotoxicity and neurotoxicity

Claim 31 covers administration of amifostine after a cisplatin-associated nephrodisorder has occurred. Claim 40 covers treatment of a cisplatin-associated neurodisorder after occurrence.

These claims are substantially narrower than claim 1 because they require:

Cisplatin exposure;
A nephrodisorder or neurodisorder;
Amifostine, or its salt or hydrate; and
Post-occurrence administration.

The narrow claims would have been easier to map onto clinical use but more limited in accused products and treatment protocols.

Xerostomia

Claims 32-35 cover treatment of xerostomia induced by antineoplastic chemotherapy or radiation therapy. Claims 33 and 35 specifically address the phosphorothioate formula and amifostine.

Unlike claims 1 and 14, these claims do not expressly require administration after xerostomia has appeared. They require a human "in need thereof" and treatment of chemotherapy- or radiation-induced xerostomia. This creates a broader timing position for xerostomia, although the claims still require a causal link to antineoplastic treatment.

How important is the “after toxicity” limitation?

The timing limitation is the main claim-construction issue.

Claims 1 and 14 require treatment "after one or more of said toxicities have occurred." Claims 38 and 39 clarify the timing by referring to:

The first indication of toxicity; and
Toxicity that has appeared and been established.

Claim 8 further specifies administration one or more days after toxicity occurs.

A treatment administered before chemotherapy, before radiation, or contemporaneously as a prophylactic cytoprotective measure would not ordinarily satisfy the express post-occurrence limitation in claims 1 and 14. A protocol could create infringement exposure only if the aminothiol was administered after the claimed toxicity had appeared or was established.

The prosecution history would be important in determining whether "after" means after objective clinical diagnosis, after symptoms, after laboratory evidence, or after the first indication of toxicity. The claim language itself supports a factual inquiry into timing, diagnosis and treatment records.

What chemotherapy agents are covered?

Claim 13 identifies:

Cisplatin
Carboplatin
Paclitaxel
Docetaxel
Vinblastine
Vincristine
Navelbine
Gemcitabine
Etoposide
Doxorubicin
Daunorubicin
Combinations of those agents

Claim 12 more broadly refers to antineoplastic agents. The claim set therefore reaches beyond platinum chemotherapy, although claims 31, 36 and 40 narrow the subject matter to cisplatin.

The wording "associated with" and "induced by" requires a causal or clinical association between the antineoplastic treatment and the toxicity. The patent does not require that the aminothiol be administered in the same treatment cycle, but the more remote the treatment, the greater the causation and timing issues.

What routes and doses are claimed?

Claim 26 identifies the following routes:

Intravenous
Subcutaneous
Intramuscular
Intradermal
Topical
Oral

Claim 10 recites approximately 10 mg/m² to 2,000 mg/m². Claims 23 and related claims repeat the dose range.

The dose limitation is dependent rather than universal. A method falling within claim 1 does not necessarily require the 10-2,000 mg/m² range unless the relevant dependent claim is asserted. The broad independent claims require a therapeutically effective amount but do not impose the numerical dose range.

The route claim is also dependent. An accused method using intravenous amifostine would fall within the listed-route limitation if the underlying independent claim were otherwise satisfied.

How strong are the claims technically and legally?

The claim set has meaningful breadth but several potential validity and enforcement pressure points.

Breadth

The broadest claims combine:

A large aminothiol genus;
Multiple chemotherapy or radiation exposures;
Multiple toxicities;
Multiple routes;
A dose range;
Salts, hydrates, metabolites and prodrugs.

That breadth gives the claims theoretical reach across many cytoprotective compounds. The practical scope is narrower because the claims must be supported by the specification and enabled across the full genus.

Written description and enablement

A defendant could challenge the broad Markush claims under written-description and enablement doctrines if the specification disclosed only a limited number of aminothiols or limited clinical evidence. The risk is greatest for:

Compounds at distant points in the claimed structural genus;
Unidentified prodrugs;
Unidentified active metabolites;
All listed toxicities across all chemotherapy agents and radiation modalities.

The narrower claims directed to amifostine, cisplatin nephrotoxicity, cisplatin neurotoxicity and xerostomia would generally present a more defined validity profile.

Indefiniteness and drafting defects

The claim set contains drafting irregularities, including:

"A active metabolite" rather than "an active metabolite";
Inconsistent capitalization and spacing;
The reference in claim 26 to "claim 1 or 20," even though claim 20 is itself dependent on claim 14;
The apparent use of claim 20 as a route-dependent reference for radiation-toxicity treatment.

These defects do not automatically invalidate the claims. Their effect would depend on whether a skilled person could determine claim scope after considering the specification and prosecution history.

Method-of-treatment proof

Infringement would generally require evidence of the actual treatment protocol. Relevant evidence could include:

Medication administration records;
Timing of toxicity onset;
Laboratory or clinical findings;
Physician notes;
Chemotherapy and radiation records;
Dose and route;
The indication documented for amifostine use.

This makes the patent less suited to a simple product-based infringement case than a composition patent.

When did US Patent 5,994,409 lose exclusivity?

The patent’s ordinary term expired approximately 20 years after its earliest effective nonprovisional filing date, likely in the 2016-2017 period. The exact terminal date requires the USPTO patent-term-adjustment calculation and the complete priority chain.

No current enforceable exclusion should be assumed from the patent number alone. A term calculation should review:

The earliest US nonprovisional filing;
Any continuation or continuation-in-part status;
Patent-term adjustment;
Terminal disclaimers;
Any patent-term extension;
Reexamination or reissue history.

Amifostine is not a biologic. Biosimilar exclusivity and the Biologics Price Competition and Innovation Act do not apply. Any later competitor would use the generic-drug framework, not a biosimilar pathway.

What is the FDA and Orange Book position?

Amifostine was approved by the FDA as Ethyol for protective indications associated with chemotherapy and radiation treatment. FDA labeling identifies uses including reduction of cumulative renal toxicity associated with cisplatin and reduction of moderate-to-severe xerostomia in patients receiving postoperative radiation for head and neck cancer (FDA, 2023).

The Orange Book analysis must distinguish FDA approval from patent enforceability:

A drug can remain FDA-approved after an associated patent expires.
A patent can be listed in the Orange Book only if it meets FDA listing requirements.
A method-of-use patent does not automatically block every generic presentation.
A generic applicant may address a listed patent through Paragraph IV certification, a section viii statement, or another applicable certification pathway.

Patent No. 5,994,409 should not be treated as a current Orange Book barrier without confirming the current FDA listing data for the relevant NDA and product presentation. The patent’s apparent expiration also means that any historical listing would not ordinarily create a current period of exclusion.

Were there Paragraph IV challenges or generic-entry disputes?

A Paragraph IV certification would have been commercially relevant only while the patent remained unexpired and listed for the applicable approved use. Because Patent No. 5,994,409 is an old method patent with an estimated 2016-2017 expiration, any Paragraph IV dispute would be historical rather than a current barrier.

The record supplied does not establish a specific Paragraph IV notice letter, ANDA number, 30-month stay, district-court complaint or settlement agreement tied to this patent. No such event should be attributed to the patent without confirmation from FDA, PACER, or a patent-litigation database.

What other patent rights matter for amifostine?

The relevant patent landscape is broader than Patent No. 5,994,409.

Patent category	Commercial relevance	Likely status
Amifostine composition patents	Protect the active compound or chemical class	Expected to be expired
Manufacturing and synthesis patents	Can affect API cost, purity and supply	Mostly expired or jurisdiction-specific
Formulation patents	Cover injectable stability, excipients, concentration or packaging	Must be checked patent by patent
Method-of-use patents	Cover renal protection, xerostomia or other indications	Many older rights are expired
Combination-treatment patents	Cover amifostine with particular cytotoxic regimens	Scope depends on claim language and term
Process and impurity patents	May affect commercial API manufacture	Potentially relevant only if later-filed
Regulatory exclusivity	FDA approval-based exclusivity	Separate from patent rights and generally time-limited

The original development history of amifostine also means that US government-funded research, military-development rights and institutional licensing may appear in the historical record. Those rights are distinct from the expired claims of Patent No. 5,994,409 and do not automatically create a current exclusionary position.

How does amifostine compare with competing cytoprotective products?

Amifostine is a small-molecule aminothiol administered primarily by injection. It differs from later supportive-care products such as sodium thiosulfate, which has separate chemistry, clinical indications and patent questions.

Attribute	Amifostine	Sodium thiosulfate
Drug type	Small-molecule aminothiol prodrug	Inorganic sulfur donor
Principal historic use	Cisplatin renal protection and radiation-associated xerostomia	Specific ototoxicity and other supportive-care uses
Regulatory pathway	Conventional NDA/ANDA framework	Conventional drug framework
Biosimilar exposure	None	None
Patent 5,994,409 relevance	Directly covers post-toxicity aminothiol treatment	Does not cover sodium thiosulfate
Main legal risk	Historical method-of-use and formulation rights	Separate product and use patents

Patent No. 5,994,409 does not broadly control all cytoprotective treatment. It controls only methods meeting its chemical, clinical and timing limitations.

What generic-launch risks remain?

For a current generic or 505(b)(2) entrant, the major risks are unlikely to arise from Patent No. 5,994,409 itself. The relevant diligence points are:

Current Orange Book listings for the reference product.
Later-expiring formulation or manufacturing patents.
Labeling that includes the patented indication.
Section viii carve-out feasibility.
Clinical-use evidence showing whether amifostine is used after toxicity or prophylactically.
API supply and manufacturing constraints.
Product presentation, including vial strength, reconstitution and storage.
Any current FDA exclusivity or market-status issue unrelated to the 1999 patent.

A generic label limited to non-patented indications can reduce method-of-use exposure, but physician prescribing and induced-infringement issues must still be assessed against the marketed label and promotional conduct.

Key Takeaways

US Patent 5,994,409 claims post-occurrence treatment of chemotherapy- and radiation-induced toxicities with aminothiol compounds.
Amifostine and WR-1065 are expressly within the claim set.
Claims 31 and 40 specifically target post-cisplatin nephrotoxicity and neurotoxicity.
Claims 32-35 address chemotherapy- or radiation-induced xerostomia.
The "after toxicity has occurred" limitation is central to infringement analysis.
The patent is a method-of-treatment patent, not a basic amifostine composition patent.
Its ordinary US patent term appears to have ended approximately in 2016-2017, subject to the official USPTO term calculation.
It does not create biosimilar risk because amifostine is not a biologic.
Current commercial exposure depends primarily on later patents, FDA listings, formulation rights, manufacturing rights and product-specific regulatory status.

FAQs

Does US Patent 5,994,409 cover prophylactic amifostine use?

Generally no for claims 1 and 14, because those claims require administration after one or more toxicities have occurred. The xerostomia claims have different timing language and should be analyzed separately.

Does the patent cover WR-1065 separately from amifostine?

Yes. Claim 2 expressly lists WR-1065, and claim 5 covers an active metabolite of WR-2721. Amifostine is WR-2721, while WR-1065 is its active dephosphorylated metabolite.

Does the patent cover treatment of cisplatin ototoxicity?

Potentially under the broader toxicity claims if the aminothiol, timing, dosage and other limitations are met. The patent does not have a narrow independent claim directed specifically to cisplatin ototoxicity.

Can a generic applicant rely on patent expiration instead of filing a Paragraph IV certification?

For an expired patent, the patent generally does not create a continuing patent bar. The applicant must still address any other unexpired Orange Book-listed patents and applicable FDA certification requirements.

Are amifostine manufacturing processes protected by this patent?

No. Patent No. 5,994,409 primarily claims therapeutic methods. It does not, based on the supplied claims, claim a manufacturing process, API synthesis, formulation composition or device.

References

U.S. Patent No. 5,994,409. (1999). Use of aminothiol compounds for treatment of toxicity. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2023). Ethyol (amifostine) prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
United States Patent and Trademark Office. (2024). Manual of Patent Examining Procedure, Chapter 2700: Patent term. USPTO.
U.S. Code, 35 U.S.C. §§ 154, 271, 355. (2024). Patents and approved drug products. lodges.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	326956	⤷ Start Trial
Australia	1718499	⤷ Start Trial
Australia	739068	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,994,409

Summary for Patent: 5,994,409